in Wound Care
PATHELEN® Chronical Wound Treatment
A new therapy to treat wound infections also with MRSA, MDR, ESBL, and other antibiotic-resistant-bacteria (Superbugs)
PAWT is a unique therapy which cures the most common chronic wound diseases such as diabetic foot ulcer (DFS), pressure ulcer (Dekubitus), and venous ulcers (ulcus cruris).
Through its revolutionary strategy, a local physical adsorption treatment of wound bacteria is used instead of the traditional approach of a systemic antibiotic treatment. PAWT can even successfully treat “hard-to heal” wound infections, which are “protected” by a Biofilm or wounds which are contaminated with antibiotic resistant MRSA and Extended spectrum beta lactamases (ESBL) producing bacteria like Escherichia coli (EHEC; E.coli) and Klebsiella.
The unique effect of PATHELEN® THERAPY is achieved through various simultaneous complex mechanisms of:
- Prevention and elimination of the biofilm
- Sorption of pus and toxins (including large amounts of problematic lipopolysaccharides)
- Preparation of a physiological wound environment with granulating tissue
The first ambulant PAWT facility is planned to open in Switzerland in 2020.
It can be observed that the general condition of a patient improves significantly after the first application of Pathelen® along with a decrease in wound pain. Additionally, the application of the first PATHELEN® Treatment reduces the risk of a sepsis significantly.
CASE STUDIES
Successful treatments of MRSA infected wounds
You don’t have an account yet? Request one directly: info@pathelen.com
Case Studie: Z.V. male, 68 y.o.
Diagnosis
- Type 2 diabetes mellitus
- diabetic foot syndrome neuroischemic form;
- wound infection of the left foot after amputation of fingers.
Microflora
- Staphylococcus aureus
- Staphylococcus epidermidis
- Enterococcus faecium
Case relevant history
- Ischemic heart disease
- Hypertensive heart disease
- Heart failure
- Atrial fibrillation is a permanent form
| Date | Day of treatment | White blood cells | Banded neutrophils |
|---|---|---|---|
| 2015-04-20 | 1 (before surgery) | 14.0×109/L | 19% |
| 2015-04-20 | 1 (after surgery) | 12.3×109/L | 15% |
| 2015-04-21 | 2 (start treatment by Pathelen) | 11.9.x109/L | 15% |
| 2015-04-22 | 3 | 10.0×109/L | 11% |
| 2015-04-28 | 4 | 9.8×109/L | 12% |
| 2015-04-24 | 5 | 8.0.x109/L | 7% |
| 2015-04-25 | 6 | 8.0×109/L | 6% |
| 2015-04-28 | 9 | 7.8×109/L | 5% |
| 2015-04-30 | 11 | 7.3×109/L | 6% |
| 2015-05-02 | 13 | 7.5×109/L | 5% |
| 2015-05-05 | 16 | 7.2×109/L | 5% |